文献速递糖尿病肥胖与代谢综合征

SGLT2抑制剂对心血管代谢疾病谱中心力衰竭结局和心血管死亡的影响:系统综述与Meta分析

Effect of SGLT2 inhibitors on heart failure outcomes and cardiovascular death across the cardiometabolic disease spectrum: a systematic review and meta-analysis.
PubMed 文献 · Lancet Diabetes Endocrinol · 2024-05-17

该系统综述与Meta分析纳入15项大型试验(N=100 952),评估SGLT2抑制剂在心力衰竭、2型糖尿病、慢性肾脏病和动脉粥样硬化性心血管疾病患者中对心力衰竭结局和心血管死亡的影响。结果显示SGLT2抑制剂在各疾病人群中均降低首次心力衰竭住院和心血管死亡风险,且在大多数亚组中一致。

要点

  • SGLT2抑制剂降低首次心力衰竭住院风险:心力衰竭29%、2型糖尿病28%、慢性肾脏病32%、动脉粥样硬化性心血管疾病28%。
  • SGLT2抑制剂降低心血管死亡风险:心力衰竭14%、2型糖尿病15%、慢性肾脏病11%、动脉粥样硬化性心血管疾病13%。
  • 急性心肌梗死和射血分数保留的心力衰竭患者中,SGLT2抑制剂对心血管死亡无效应。

核心结论

  • SGLT2抑制剂降低心力衰竭、2型糖尿病、慢性肾脏病和动脉粥样硬化性心血管疾病患者的心力衰竭事件和心血管死亡风险。
  • 这些效应在这些人群的广泛亚组中一致。
  • 这支持心血管-肾脏-代谢疾病广大人群有资格接受SGLT2抑制剂治疗。

研究设计与样本

  • 系统综述与Meta分析,检索PubMed、Cochrane CENTRAL和SCOPUS截至2024年2月10日,纳入大型试验(n>1000)的一级和二级分析。
  • 纳入15项试验,共100 952例患者,涵盖心力衰竭、2型糖尿病、慢性肾脏病和动脉粥样硬化性心血管疾病(包括急性心肌梗死)。
  • 使用随机效应模型合并效应量,研究注册于PROSPERO,CRD42024513836。

主要发现

  • 与安慰剂相比,SGLT2抑制剂降低首次心力衰竭住院风险:心力衰竭患者29%(HR 0.71 [95% CI 0.67-0.77]),2型糖尿病患者28%(0.72 [0.67-0.77]),慢性肾脏病患者32%(0.68 [0.61-0.77]),动脉粥样硬化性心血管疾病患者28%(0.72 [0.66-0.79])。
  • SGLT2抑制剂降低心血管死亡风险:心力衰竭患者14%(HR 0.86 [95% CI 0.79-0.93]),2型糖尿病患者15%(0.85 [0.79-0.91]),慢性肾脏病患者11%(0.89 [0.82-0.96]),动脉粥样硬化性心血管疾病患者13%(0.87 [0.78-0.97])。
  • 在研究的51个亚组中大多数亚组,SGLT2抑制剂对首次心力衰竭住院和心血管死亡的获益一致。
  • notable exceptions包括急性心肌梗死(首次心力衰竭住院降低22%;对心血管死亡无效应)和射血分数保留的心力衰竭(首次心力衰竭住院降低26%;对心血管死亡无效应)。

关键数值与推荐

  • SGLT2抑制剂降低首次心力衰竭住院风险:心力衰竭HR 0.71(95% CI 0.67-0.77),2型糖尿病HR 0.72(0.67-0.77),慢性肾脏病HR 0.68(0.61-0.77),动脉粥样硬化性心血管疾病HR 0.72(0.66-0.79)。
  • SGLT2抑制剂降低心血管死亡风险:心力衰竭HR 0.86(95% CI 0.79-0.93),2型糖尿病HR 0.85(0.79-0.91),慢性肾脏病HR 0.89(0.82-0.96),动脉粥样硬化性心血管疾病HR 0.87(0.78-0.97)。
  • 急性心肌梗死患者首次心力衰竭住院降低22%,对心血管死亡无效应;射血分数保留的心力衰竭患者首次心力衰竭住院降低26%,对心血管死亡无效应。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Sodium-glucose co-transporter-2 (SGLT2) inhibitors have been studied in patients with heart failure, type 2 diabetes, chronic kidney disease, atherosclerotic cardiovascular disease, and acute myocardial infarction. Individual trials were powered to study composite outcomes in one disease state. We aimed to evaluate the treatment effect of SGLT2 inhibitors on specific clinical endpoints across multiple demographic and disease subgroups. METHODS: In this systematic review and meta-analysis, we queried online databases (PubMed, Cochrane CENTRAL, and SCOPUS) up to Feb 10, 2024, for primary and secondary analyses of large trials (n>1000) of SGLT2 inhibitors in patients with heart failure, type 2 diabetes, chronic kidney disease, and atherosclerotic cardiovascular disease (including acute myocardial infarction). Outcomes studied included composite of first hospitalisation for heart failure or cardiovascular death, first hospitalisation for heart failure, cardiovascular death, total (first and recurrent) hospitalisation for heart failure, and all-cause mortality. Effect sizes were pooled using random-effects models. This study is registered with PROSPERO, CRD42024513836. FINDINGS: We included 15 trials (N=100 952). Compared with placebo, SGLT2 inhibitors reduced the risk of first hospitalisation for heart failure by 29% in patients with heart failure (hazard ratio [HR] 0·71 [95% CI 0·67-0·77]), 28% in patients with type 2 diabetes (0·72 [0·67-0·77]), 32% in patients with chronic kidney disease (0·68 [0·61-0·77]), and 28% in patients with atherosclerotic cardiovascular disease (0·72 [0·66-0·79]). SGLT2 inhibitors reduced cardiovascular death by 14% in patients with heart failure (HR 0·86 [95% CI 0·79-0·93]), 15% in patients with type 2 diabetes (0·85 [0·79-0·91]), 11% in patients with chronic kidney disease (0·89 [0·82-0·96]), and 13% in patients with atherosclerotic cardiovascular disease (0·87 [0·78-0·97]). The benefit of SGLT2 inhibitors on both first hospitalisation for heart failure and cardiovascular death was consistent across the majority of the 51 subgroups studied. Notable exceptions included acute myocardial infarction (22% reduction in first hospitalisation for heart failure; no effect on cardiovascular death) and heart failure with preserved ejection fraction (26% reduction in first hospitalisation for heart failure; no effect on cardiovascular death). INTERPRETATION: SGLT2 inhibitors reduced heart failure events and cardiovascular death in patients with heart failure, type 2 diabetes, chronic kidney disease, and atherosclerotic cardiovascular disease. These effects were consistent across a wide range of subgroups within these populations. This supports the eligibility of a large population with cardiorenal-metabolic diseases for treatment with SGLT2 inhibitors. FUNDING: None.

来源:Lancet Diabetes Endocrinol,查看原文。版权归原作者所有。

引用

  1. Usman MS, Bhatt DL, Hameed I, et al. Effect of SGLT2 inhibitors on heart failure outcomes and cardiovascular death across the cardiometabolic disease spectrum: a systematic review and meta-analysis. Lancet Diabetes Endocrinol. 2024. PMID: 38768620. doi:10.1016/S2213-8587(24)00102-5

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。